Skip to main content
Skip to footer
Dicerna Pharmaceuticals
Dicerna
Careers at Dicerna
News
Contact
Search for:
Search Button
Our
Company
Collaborating
Grants & Charitable Donations
Our GalXC™ and GalXC-Plus™ Technologies
Scientific Publications
Pipeline
Nedosiran (formerly DCR-PHXC)
RG6346 (formerly DCR-HBVS)
Belcesiran (formerly DCR-A1AT)
DCR-AUD
Collaborative Programs
Clinical Trials
Patients
A Message To Our Patients
Patient Advocacy Charter
Primary Hyperoxaluria (PH)
Hepatitis B Virus
Alpha-1 Antitrypsin Deficiency-associated Liver Disease
Alcohol Use Disorder (AUD)
Press Releases & Presentations
Press Releases
Events & Presentations
News
News
Share this page:
Our
Company
Collaborating
Grants & Charitable Donations
Our GalXC™ and GalXC-Plus™ Technologies
Scientific Publications
Pipeline
Nedosiran
(DCR-PHXC)
RG6346 (formerly DCR-HBVS)
Belcesiran (formerly DCR-A1AT)
DCR-AUD
Collaborative Programs
Clinical Trials
Patients
A Message To Our Patients
Patient Advocacy Charter
Primary Hyperoxaluria (PH)
Hepatitis B Virus
Alpha-1 Antitrypsin Deficiency-associated Liver Disease
Alcohol Use Disorder (AUD)
Press Releases & Presentations
Press Releases
Events & Presentations
Careers at Dicerna
Contact
Effective 28 December 2021 Dicerna Pharmaceuticals, Inc. is a wholly owned subsidiary of Novo Nordisk A/S
PRESS RELEASE
CONTINUE TO DICERNA.COM
VISIT NOVONORDISK.COM